NeuroSense’s PrimeC Shows 65% ALS Death Risk Reduction, Secures Phase 3 Clearance
NeuroSense advanced PrimeC into a late-stage ALS therapy with FDA Phase 3 clearance after Phase 2b data showed a 65% risk-of-death reduction and a >14-month median survival benefit. The company posted an $11.1M net loss in 2025, R&D up 8.8% to $6.2M and cash down to $0.2M.
1. Clinical and Regulatory Progress
NeuroSense advanced PrimeC with Phase 2b PARADIGM results showing a 65% reduction in risk of death and a >14-month median survival benefit, culminating in FDA clearance to initiate the PARAGON Phase 3 ALS trial.
2. Financial Performance
For 2025, NeuroSense reported a net loss of $11.1M, with R&D expenses of $6.2M (up 8.8%) and G&A expenses of $4.9M (up 16.6%); cash and equivalents totaled $0.2M, leaving a shareholders’ deficit of $1.56M.
3. Upcoming Regulatory Milestones
The company is preparing for a pre-NDS meeting with Health Canada in May 2026, potential Canadian NDS submission, imminent biomarker readouts from PARADIGM and planned initiation of the PARAGON Phase 3 trial.
4. Pipeline Expansion and IP Strength
Early Alzheimer's biomarker signals support broader neurodegenerative potential, while newly granted international patents and an expanded Scientific Advisory Board bolster PrimeC’s development strategy.